BeOne Medicines Ltd.

# Investment Summary: BeOne Medicines - Tislelizumab ESCC Trial **Clinical Finding:** The EC-CRT-002 trial demonstrated that tislelizumab (an anti-PD-L1 checkpoint inhibitor) combined with induction chemotherapy and concurrent chemoradiotherapy improved efficacy outcomes in locally advanced esophageal squamous cell carcinoma (ESCC), a disease with limited treatment options and significant unmet medical need in Asian markets. **Commercial Implications:** This positive Phase II data supports advancement toward registration in ESCC, potentially establishing tislelizumab in a new indication with meaningful market opportunity, particularly in China and other high-incidence regions where ESCC represents a major cancer burden. However, investors should monitor upcoming Phase III readouts and regulatory timelines, as the competitive immunotherapy landscape in solid tumors remains crowded with established checkpoint inhibitors. **Key Risk:**

# Investment Summary: BeOne Medicines (BEIGF) **Clinical Finding:** This case report documents a patient with Bing-Neel syndrome (CNS lymphoplasmacytic lymphoma) who progressed on ibrutinib but responded to zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor, suggesting potential efficacy in ibrutinib-resistant disease. **Investor Implications:** The data supports a clinical rationale for zanubrutinib in BTK inhibitor-resistant populations, which could expand the addressable market beyond first-line use and strengthen competitive positioning against ibrutinib. However, this represents a single case report rather than controlled evidence; meaningful commercial impact would require validation in prospective trials demonstrating consistent efficacy in resistant Bing-Neel syndrome—a rare indication with limited commercial scale—and potential label expansion.

# Investment Summary: BeOne Medicines Ltd. (BEIGF) **Clinical Finding:** This phase II trial demonstrates that combining preoperative chemoimmunotherapy (tislelizumab, an anti-PD-L1 monoclonal antibody) with salvage surgery and adjuvant tislelizumab produces measurable clinical responses in recurrent head-and-neck squamous cell carcinoma (HNSCC) patients with prior radiation, a heavily treatment-resistant population with limited therapeutic options. **Commercial Implication:** The data supports tislelizumab's potential in a defined, underserved indication (recurrent irradiated HNSCC) with smaller but identifiable patient populations, positioning the compound for potential regulatory approval and niche market penetration; however, investor focus should remain on comparative efficacy versus existing checkpoint inhibitors and the ultimate regulatory pathway given the specific study population. **Key